Founded in 1994 by Dr. LI Xiaoyi Benjamin, Lee’s Pharmaceutical Holdings Limited (the “Company” or “Lee’s Pharm”, together with its subsidiaries as the “Group”, HKEx: 950) is a Hong Kong listed biopharmaceutical company with more than 25 years of operation in the pharmaceutical industry in China. “We remain committed to the R&D of innovative products to address unmet medical needs and improve patients’ quality of life,” says Dr. Li.

Dr. LI Xiaoyi Benjamin, Founder & Director of Lee’s Pharmaceutical Holdings Limited

“Being a research-driven and market-oriented company, Lee’s Pharm is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing based in China with global perspectives,” he continues.

Since the company’s listing on the HKEx GEM in 2002, the Group has expanded its business operation and scope. Following the transfer of listing to the HKEx Main Board in 2010, the Group continued to scale up its business on being a successful biopharmaceutical group in Asia. Lee’s Pharmaceutical is headquartered at Hong Kong Science Park in Hong Kong, and currently operating its production facilities with two pharmaceutical manufacturing plants in Nansha and Hefei, China. The Group operates its business through two business segments: (i) proprietary and generic products; and (ii) licensed-in products. The proprietary and generic products segment manufactures and sells self-developed pharmaceutical products and the licensed-in products segment trades licensed-in pharmaceutical products

Today, the Group has established extensive partnerships with over 20 international companies and currently markets over 25 proprietary, generic and licensed-in pharmaceutical products in mainland China, Hong Kong, Macau and Taiwan. The Group focuses on several key disease areas such as cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology and obstetrics, and has more than 40 products under different development stages stemming from both internal research and development as well as from the licensing of development, commercialization, and manufacturing rights from various United States, European and Japanese companies.

For more information visit www.leespharm.com

The Mediazone Group congratulates Lee’s Pharm for winning the Most Valuable Companies in Hong Kong 2022 Awards. We wish the Group more success in its growth and endeavor.

Tagged in: